Brain Regeneration Impaired in Progressive MS, Unaffected By DMTs, Study Reports

Source Multiple Sclerosis News Today: Regeneration in the brain is reduced in people with primary progressive multiple sclerosis (PPMS), but enhanced during disease activity in those with relapsing-remitting MS (RRMS), a study reports.

The results also show that regeneration is unaffected by treatment with disease-modifying therapies (DMTs), as shown by the levels of a regeneration marker in the brain called growth-associated protein 43.

The study, “Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis,” was published in the journal Nature Scientific Reports.

In MS, immune cells attack the myelin sheath that protects nerves, leading to neurodegeneration. In early disease stages, regenerative mechanisms are activated to help repair damaged tissue and promote the replacement of lost myelin — a process called remyelination.  Read on. 

Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis

Source Pipeline Review: Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) Begins Enrollment.

The Immune Tolerance Network (ITN) opened the BEAT-MS clinical trial for enrollment. BEAT-MS or “Best Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant (AHSCT) for MS” will investigate high dose immunosuppression followed by AHSCT – a type of transplant using a patient’s own immune stem cells – compared to the best medical treatment currently available for multiple sclerosis (MS) in participants with relapsing MS.  Read on. 

Plegridy approved for relapsing remitting MS in England

Source MS Trust: NICE has published its final decision recommending that Plegridy can be prescribed by the NHS for relapsing-remitting MS.

In May 2018, NICE carried out a review of several of the MS drugs and decided that Avonex, Extavia, Rebif, Copaxone and Brabio should continue to be available on the NHS in England. At the time, NICE was unable to make a recommendation on Plegridy and has now completed a separate appraisal.  Read on. 

Search About us Blog Membership Contact Newsletters Home How we can help Your first visit About MS Support us Events Donate The MS Society went to 10 Downing Street with their ambassador Janis Winehouse

Source MS Society: The MS Society went to 10 Downing Street yesterday with their ambassador Janis Winehouse and campaigner Ashley Arundale to deliver a message to the PM: Unfair PIP assessments must change.

“More than 21,000 of us have signed an open letter demanding the UK Government makes changes to Personal Independence Payment (PIP). The open letter came after our research showed major flaws with the system.

It highlights some of our concerns with PIP, including uninformed assessors, inaccurate reports and excessively complex forms.

Our Downing Street delivery team was made up of people from our campaigns team and our wider MS community – including our MS Society Ambassador Janis Winehouse who has secondary progressive MS and campaigner Ashley Arundale who has relapsing MS.”  Read on. 

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART)

Source The Lancet: Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in an efficient manner with respect to time, cost, and patient resource.


We did a phase 2b, multiarm, parallel group, double-blind, randomised placebo-controlled trial at 13 clinical neuroscience centres in the UK. We recruited patients (aged 25–65 years) with secondary progressive multiple sclerosis who were not on disease-modifying treatment and who had an Expanded Disability Status Scale (EDSS) score of 4·0–6·5. Participants were randomly assigned (1:1:1:1) at baseline, by a research nurse using a centralised web-based service, to receive twice-daily oral treatment of either amiloride 5 mg, fluoxetine 20 mg, riluzole 50 mg, or placebo for 96 weeks. The randomisation procedure included minimisation based on sex, age, EDSS score at randomisation, and trial site. Capsules were identical in appearance to achieve masking. Patients, investigators, and MRI readers were unaware of treatment allocation. The primary outcome measure was volumetric MRI percentage brain volume change (PBVC) from baseline to 96 weeks, analysed using multiple regression, adjusting for baseline normalised brain volume and minimisation criteria. The primary analysis was a complete-case analysis based on the intention-to-treat population (all patients with data at week 96).  Read on. 

Siponimod licensed for secondary progressive MS

Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease.

That makes siponimod the first and only oral treatment in Europe specifically for patients with secondary progressive MS with active disease.

What was the evidence?

The drug approval is based on the Phase III EXPAND trial, the largest randomised clinical study of people with secondary progressive MS.

This trial showed taking siponimod significantly reduced the risk of disease progression, including physical disability and cognitive effects.

Who can have siponimod (Mayzent)?

Siponimod hasn’t been recommended for everyone with secondary progressive MS. It’s only been recommended for people who have evidence of inflammatory activity on an MRI scan or who still have relapses.  Read on.

Do you have any unwanted Christmas presents?

We would be grateful for donations of any unwanted Christmas presents that we can use for raffle prizes.

Please bring them to the Centre and we can find them a loving home whilst raising much-needed funds for the Centre!

Funeral Friday 17th January

Message received from Beryl’s daughter…..

Thank you so much for your reply; and kind words. It’s still hard to believe she’s gone and we miss her.

The funeral is this Friday 17th January at 11amGarden House, Milton Hill, Steventon, Oxon OX13 6AF

You would be very welcome and please could you let her other friends at the centre know they are welcome too. Refreshments will be served later after the burial at 1pm at Garden House.